Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Recruiting

Phase 2

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Sponsor:

MBX Biosciences

Code:

NCT06531941

Conditions

Hypoparathyroidism

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

400 µg of MBX 2109 once-weekly by subcutaneous injection

200-1600 µg of MBX 2109 once-weekly by subcutaneous injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by MBX Biosciences on 2024-11-12.